Company Focus
Chiesi Farmaceutici
Latest Chiesi Farmaceutici News
Pharmaceutical
Family-controlled Italian drugmaker Chiesi Group has announced financial results for the six months ended June 30, 2025. 16 September 2025
Related News
Insights
Company Spotlight
The company operates as a U.S.-based cardiovascular biopharmaceutical developer with additional corporate functions outside California to support clinical operations, regulatory activity, and commercialization planning.
Latest News & Features of interest to Chiesi Farmaceutici
Biotechnology
Sweden’s Sobi has announced that the European Commission (EC) has approved Aspaveli (pegcetacoplan) for adults and adolescents aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated. 16 January 2026
Biotechnology
Italian non-profit organization Fondazione Telethon today announced the European Commission’s decision of January 9, to grant marketing authorization for Waskyra (etuvetidigene autotemcel), an ex vivo gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS), a rare and severe genetic immunodeficiency. 16 January 2026
Pharmaceutical
DelveInsight says the US hemophagocytic lymphohistiocytosis (HLH) market was worth about $140 million in 2024, reflecting a small but high-need patient population and outcomes that remain challenging even with aggressive care. 16 January 2026
Pharmaceutical
Japanese drugmaker Tanabe Pharma said its oral candidate dersimelagon met the primary endpoint and showed a favorable safety profile in INSPIRE, a global Phase III trial in erythropoietic protoporphyria and X-linked protoporphyria, two ultra-rare disorders marked by painful reactions to light. 16 January 2026
Pharmaceutical
China’s National Medical Products Administration has approved two innovative medicines licensed to French pharma major Sanofi, Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), and Redemplo (plozasiran) for the reduction of triglyceride levels, in adult patients with familial chylomicronaemia syndrome (FCS) on the basis of dietary control. 15 January 2026
Pharmaceutical
US biotech Biogen said the European Commission on January 12, 2026 granted marketing authorization for a higher-dose regimen of Spinraza (nusinersen) to treat 5q spinal muscular atrophy. The EU label has been updated to include the dosing option. 15 January 2026
Pharmaceutical
The US Food and Drug Administration yesterday approved the Zycubo (copper histidinate) injection as the first treatment for Menkes disease in pediatric patients. The FDA approved Zycubo, previously known as CUTX-101, for Sentynl Therapeutic, a part India’s Zydus Lifesciences which filed the regulatory filing and is partnered with Fortress Biotech.
. 14 January 2026
Biotechnology
Taiwan-based PharmaEssentia Corporation, a biopharma seeking to deliver new biologics in hematology and oncology, has announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for ropeginterferon alfa-2b-njft for the treatment of adult patients with essential thrombocythemia (ET). 13 January 2026
Biotechnology
Hong Kong-listed Sino Biopharmaceutical is to buy fellow Chinese firm Hangzhou Hygieia Biomedical. 13 January 2026
Biotechnology
UK-based Qureight, a tech-bio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, has announced the appointment of Rebecca Simmons as chief operating officer (COO). 13 January 2026
Latest In Brief for Chiesi Farmaceutici
Pharmaceutical
Swiss pharma company Santhera Pharmaceuticals announced that the Swiss Agency for Therapeutic Products (Swissmedic), has approved Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. 15 January 2026
Latest Relevant Ones To Watch News
Hong Kong-listed Sino Biopharmaceutical is to buy fellow Chinese firm Hangzhou Hygieia Biomedical. 13 January 2026
19 December 2025
15 December 2025
12 December 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze